WHO consultancy: Rollout of Policy Guidance on Integrated Stewardship Activities

Dear All,

Just below my signature you will find the full details on a recently posted WHO consultancy opportunity. It’s an intriguing 6-month project during which you would be responsible for the rollout and implementation of a new WHO Policy Guidance on the Implementation of Integrated Antimicrobial Stewardship Activities. This guidance will be rolled out in several regions and implementation to adapt the guidance to local contexts will start in several countries.

Even if you don’t want to apply for consultancy, you should take a look at the Policy Guidance. The guidance was created because “Member States have requested WHO policy guidance on how to facilitate the implementation of national AMS activities in an integrated and programmatic approach.” To address these requests, the guidance aims to provide a set of evidence-based and pragmatic recommendations to drive comprehensive and integrated AMS activities and has these target audiences:

  • National policy-makers at ministries of health, national AMR coordinating bodies such as national AMR steering or coordinating committees or other equivalent national authorities who are responsible for the development, implementation and monitoring of the national action plans, policies and standards for mitigating AMR in the human health sector.
  • Subnational authorities and decisionmakers, technical experts and stakeholders supporting such programmes at all levels.
  • Finally, sectors or ministries working on quality of care in the human health sector, WASH, IPC, animal and plant health as well the environment would find the policy to have important implications and relevance.

Intriguing indeed … all quite high level! Could this be you? The deadline is 9 June 2021. Sharpen your pencil and get to it!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: All opinions are my own.

Contract Type: Individual consultancy
Application deadline: COB Wednesday, 9 June 2021 (CET)
Contact: Naomi Vollet
Email address: whoams@who.int
Consultancy reference: HQ/AMR/GCP/2021/7

  1. Purpose of the Consultancy

Support the rollout and implementation of the WHO Policy Guidance on Integrated Antimicrobial Stewardship Activities

  1. Background

Antimicrobial resistance (AMR) is a global health and development threat. It requires urgent multisectoral action in order to achieve the Sustainable Development Goals (SDGs). Antimicrobials are used to fight diseases in humans, animals and plants and include antibiotic, antiviral, antifungal and antiparasitic medicines. AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result of drug resistance, antibiotics and other antimicrobial medicines become ineffective and infections become increasingly difficult or impossible to treat.
In response to demand from member states and after extensive global consultations, WHO developed a new policy guidance on the implementation of integrated antimicrobial stewardship activities. This guidance will be rolled out in several regions and implementation to adapt the guidance to local contexts will start in several countries. 
The Department of Global Coordination and Partnership on AMR leads and coordinates the global One Health multisectoral response to AMR, in cooperation with FAO, OIE, the UN as well as other agencies, civil society, and the private sector, towards a world free from the suffering of drug-resistant infections. The Department has the following functions in line with WHO’s General Programme of Work to protect antimicrobials important for human health and mitigate drug-resistant infections: Leads the global One Health multisectoral response to AMR across the human, animal, plant, food, feed and environment sectors, through multisectoral engagement and interventions, and strengthening advocacy and awareness; Facilitates global coordination and interagency engagement and partnership for creation and sustenance of shared global vision and goals; shapes the research and development agenda through innovation, priority setting and supporting global initiatives that enable the generation, translation and dissemination of knowledge; facilitates, nurtures and scales up evidence-based interventions to enhance stewardship, awareness, and understanding of AMR across the One Health spectrum.

  1. Planned timelines

This consultancy is for six months, to begin as soon as possible.

  1. Work effort

Full time (100% FTE)

  1. Work to be performed

Output: Facilitate effective implementation of the rollout of the WHO Policy Guidance on Integrated Antimicrobial Stewardship Activities across selected regions and countries
Activity 1 Engage in consultations with WHO regions and country offices to finalise activities needed to rollout the policy guidance and enable effective implementation
Activity 2 Provide technical assistance as may be required to support  effective rollout
Activity 3 Monitor progress against agreed plans and provide periodic reports of progress 
Activity 4 Monitor utilization of funds against agreed budgets and provided periodic updates on expenditures
Activity 5 Support documentation of all aspects of the rollout and share information across regions and countries
Activity 6 Develop draft reports for submission to donor(s) periodically

  1. Specific requirements

Essential: minimum first university degree in Public Health, Medicine and/or project management
Desirable: additional qualification in the above fields
Essential: At least five (5) years of experience in project management in the area of public health; communicable diseases; water sanitation and hygiene; and/or AMR.
Desirable: Previous experience with antimicrobial stewardship. Experience working in the UN.
– Technical skills and knowledge:

  • Excellent writing and editing skills
  • Excellent organizational and scheduling skills
  • Excellent interpersonal skills with the ability to build strong relationships with a variety of stakeholders across different sectors
  • Excellent analytical and presentation skills
  • Self-discipline with the ability to work with autonomy and as part of a team

WHO Competencies:

  • Communicating in a credible and effective way
  • Producing results
  • Knowing and managing yourself
  • Moving forward in a changing environment

– Language requirements:
Fluency in English (both oral and written).
An additional UN language would be an advantage.

  1. Place of assignment

The consultancy will be initiated remotely (home-based) under a teleworking arrangement. Virtual meetings with the Geneva-based GCP Department will take place during regular office hours (Central European Time). If regulations allow, a transition to work from Geneva would be strongly preferred.

  1. Travel

When the department or office concerned determines that travel is necessary in order for the consultant to perform the work, a travel request will be raised and per diem will be applied as per WHO payment regulations.

  1. Fee rate, contract duration, timing of payments and performance evaluation

The remuneration will be based on a monthly fee in the range US$7,000 – US$9,000, depending on the selected consultant’s degree of specialization, knowledge, qualifications, experience and skills. This is in accordance with the WHO remuneration scales for international consultants. The daily fee will be agreed between WHO and the selected consultant in advance. The contract will cover a 6-month period. Payments will be made following satisfactory completion of a set of deliverables. Other terms and conditions of employment will be in accordance with WHO policy on the employment of consultants (details available upon request).

  1. How to prepare and submit a proposal in reply to this tender


  1. Content of the proposal
  1. A cover letter explaining the bidder’s motivation for applying to this position.
  2. A copy, in .pdf format, of the bidder’s updated CV or Personal History Form (preferred option, detailed instructions on how to do this through the following link: http://www.who.int/careers/process/instructions-for-candidates.pdf?ua=1).
    PLEASE NOTE: The selected candidate(s) will be asked to produce copies of all degrees/diplomas/certificates as mentioned in their CVs or Personal History Forms, as well as a copy of their passport and other documents as appropriate.
  3. Full contact details.
  4. Description and contact details of at least two recent references (the references shall be related to the present Terms of Reference).

Incomplete proposals will not be considered.

  1. Questions during preparation of proposal

A prospective bidder requiring any clarification on technical, contractual or commercial matters may notify WHO via e-mail (whoams@who.int) no later than 3 June, 2021 hours, 23.59 hours Central European Time (Geneva time).

  1. Deadline for submission of proposal

The deadline for final submissions of proposals is 9 June, 2021 23.59 hours Central European Time (Geneva time).

  1. Email address for submission of proposal

Final duly completed proposals should be submitted in electronic format by e-mail to: whoams@who.int with subject reference clearly marked as reference number HQ/AMR/GCP/2021/7.
Additional Information section:

  • This vacancy notice may be used to identify candidates for other similar consultancies.
  • Only candidates under serious consideration will be contacted.
  • A written test and interview will be used as a form of screening.
  • If your candidature is retained for interview, you will be required to provide, in advance, a scanned copy of the degree(s)/diploma(s)/certificate(s) required for this position. WHO only considers higher educational qualifications obtained from an institution accredited/recognized in the World Higher Education Database (WHED), a list updated by the International Association of Universities (IAU)/United Nations Educational, Scientific and Cultural Organization (UNESCO). The list can be accessed through the link: http://www.whed.net/. Some professional certificates may not appear in the WHED and will require individual review.
  • For information on WHO’s operations please visit: http://www.who.int.
  • WHO is committed to workforce diversity.
  • WHO has a smoke-free environment and does not recruit smokers or users of any form of tobacco.
  • Applications from women and from nationals of non and underrepresented Member States are particularly encouraged.

Current funding opportunities (most current list is here):

  • MTEC has announced an RFP seeking proposals focused on diagnostics, prevention of endemic diarrhea, and selected antivirals. Go here for the full RFP and search for “FA2.13” to find the infection-focused topics. White papers are due 17 June 2021.
  • GNA NOW (part of the IMI AMR Accelerator) has an open call to identify a novel mechanism antibacterial to add to its portfolio. The selected project would receive resources equivalent up to several million € (to be defined according to project needs); see also this 11 May 2021 newsletter for details. Expressions of interest are due by 18 June 2021.
  • CARB-X recently announced that their existing resources will be reserved to fund their existing portfolio (more than 80 total awards, and counting, as they include contracting from prior rounds). New rounds from CARB-X will occur only after new funding is obtained in 2021.
  • It’s not a funder, but AiCuris’ AiCubator offers incubator support to very early stage projects. Read more about it here.
  • The Global AMR R&D Hub’s dynamic dashboard (link) summarizes the global clinical development pipeline, incentives for AMR R&D, and investors/investments in AMR R&D.
  • In addition to the lists provided by the Global AMR R&D Hub, you might also be interested in my most current lists of R&D incentives (link) and priority pathogens (link).

Upcoming meetings of interest to the AMR community (most current list is here):

  • 24-29 May 2021 (virtual and in Geneva): ESPID 2021, the 39th Annual Meeting of the European Society for Paediatric Infectious Diseases. Save-the-date announcement is here, details to follow. 
  • 26 May 2021 (virtual, 15.00-16.00 CEST): Webinar on the GNA NOW open call. See this 11 May 2021 newsletter for details on GNA NOW. Go here to register for the webinar.
  • 27 May 2021 (virtual, 9.30a-11.00 CEST): GARDP-sponsored webinar entitled “New clinical trial designs for evaluation of antimicrobial agents.” Go here to register.
  • 7-9 Jun 2021 (virtual, various times): 5th International Conference on Responsible Use of Antibiotics in Animals. This conference runs only every few years … the 4th instance was in 2016. Go here to register.
  • 20-24 Jun 2021 (Toronto): International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-12). Go here for details.
  • 20-24 Jun 2021 (virtual, various times): World Microbe Forum sponsored by the American Society for Microbiology (ASM) and the Federation of European Microbiological Societies (FEMS). Go here for more details and to register.
  • 24 Jun 2021 (virtual, 09:30 AM – 05:30 PM CEST): Workshop entitled “Advancing Data Technologies to corner AMR.” Sponsored by AMR Insights, you can register here.
  • 27 Jun-2 Jul 2021 (Ventura, CA): Gordon Research Conference entitled “Antimicrobial Peptides”. Go here for details, go here for the linked 26-27 Jun Gordon Research Seminar that precedes it.
  • 9-12 Jul 2021 (virtual): Annual ECCMID meeting (#31)
  • 26 Jul-30 Jul 2021 (online): Small World Initiative Instructor Training Workshop – training for undergraduate professors in the wet lab techniques, parallel curricula, & pedagogical instruction to engage students in the hunt to find new antibiotic-producing soil microbes. Go here to register.
  • 14-29 Aug 2021 (Marine Biology Laboratory, Woods Hole, MA): Residential course entitled “Molecular Mycology: Current Approaches to Fungal Pathogenesis.” This 2-week intensive training program has run annually for many years and gets outstanding reviews. Go here for details.
  • 24-26 Aug 2021 (virtual, timings not stated but presumably EU-centered): The 5th edition of the annual AMR conference sponsored by the BEAM Alliance, CARB-X, the Novo REPAIR Impact Fund, the IMI Accelerator, and the European Biotechnology Network. The in-person version of this meeting is consistently excellent; the video-based version will have to do for 2021. Go here for details. 
  • 8-11 Oct 2021 (Aberdeen, Scotland): 10th Trends in Medical Mycology. Go here for details.
  • 11-15 Oct 2021 (physical, somewhere in the UK): UK-focused Innovation Mission sponsored by Innovate UK in collaboration with AMR Insights and Oxford innovation. This free event seeks to connect AMR-focused start-ups, SMEs and Multinationals, Academia, Research Institutes, Regional Development Companies and other interested stakeholders in the UK, Europe and other parts of the world. Go here for more details.
  • 16-24 Oct 2021 (Annecy, France): Interdisciplinary Course on Antibiotics and Resistance (ICARe). This is a soup-to-nuts residential course on antibiotics, antibiotic resistance, and antibiotic R&D. The course is very intense, very detailed, and gets rave reviews. Registration is here and is limited to 40 students. Bonus feature: For obvious reasons, the course didn’t happen in 2020! But as a celebration of the course’s 5th year, a webinar version was held on 29 Oct 2020: go here to stream it. 
  • 25-28 Oct 2021 (Stellenbosch, South Africa): The University of Cape Town’s H3D Research Centre will celebrate its 10th anniversary with a symposium covering the Centre’s research on Malaria, TB, Neglected Tropical Diseases, and AMR. Go here to register.
  • 5-8 Nov 2021 (Albuquerque, New Mexico): Biannual meeting of the MSGERC (Mycoses Study Group Education and Research Consortium). Save-the-date announcement is here, details to follow.
  • 6-11 Mar 2022 (Il Ciocco, Tuscany): Gordon Research Conference entitled “New Antibacterial Discovery and Development”. Go here for details, go here for the linked 5-6 Mar Gordon Research Seminar that precedes it.


ENABLE-2 funding now includes Hit Identification & Validation

Dear All, I wrote on 25 Aug 2023 about the ENABLE-2 program and its support for hit-to-lead compound development. As a reminder, that program is focused on molecules with the potential to be direct-acting therapies for one or more of the following priority pathogens: ESBL-producing/carbapenem-resistant Enterobacteriaceae (E. coli, K. pneumoniae), P. aeruginosa, A. baumannii, methicillin-resistant S. aureus, or vancomycin-resistant E. faecium. Adding to that program, there is now an ENABLE-2

NIAID/DMID thinking for FY2026: Antibacterials, Phage, and Antifungals

Dear All, NIAID’s DMID (Division of Microbiology and Infectious Diseases) recently held a council meeting during which they proposed program concepts that encompassed both antibacterial therapies (including phage) as well as antifungal therapies for funding in FY 2026 (the year that would run from 1 Oct 2025 to 30 Sep 2026). There is no guarantee that

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

The (confusing!) language of AMR: ChatGPT tries to help!

Dear All (Wonkish alert! Not technical but lengthy … so settle in and enjoy the ride!): Regular readers will know of my fascination with language: e.g., this 20 Feb 2020 newsletter entitled “Language Matters: CRE vs. CPE; SDD vs. I; And MDR, XDR, PDR, UDR vs. DTR.” How about that for acronymics taken to Olympian

Scroll to Top